These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23483908)

  • 41. Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study.
    Rousseau F; Langlois S; Johnson JA; Gekas J; Bujold E; Audibert F; Walker M; Giroux S; Caron A; Clément V; Blais J; MacLeod T; Moore R; Gauthier J; Jouan L; Laporte A; Diallo O; Parker J; Swanson L; Zhao Y; Labelle Y; Giguère Y; Forest JC; Little J; Karsan A; Rouleau G
    Eur J Hum Genet; 2019 Nov; 27(11):1701-1715. PubMed ID: 31231136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Confined placental origin of the circulating cell free fetal DNA revealed by a discordant non-invasive prenatal test result in a trisomy 18 pregnancy.
    Mao J; Wang T; Wang BJ; Liu YH; Li H; Zhang J; Cram D; Chen Y
    Clin Chim Acta; 2014 Jun; 433():190-3. PubMed ID: 24667696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical application of noninvasive prenatal diagnosis using cell free fetal DNA in maternal plasma].
    Hou QF; Wu D; Chu Y; Kang B; Liao SX; Yang YL; Zhang CY; Zhang JX; Wu G
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):813-7. PubMed ID: 23302120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
    Chiu RW; Akolekar R; Zheng YW; Leung TY; Sun H; Chan KC; Lun FM; Go AT; Lau ET; To WW; Leung WC; Tang RY; Au-Yeung SK; Lam H; Kung YY; Zhang X; van Vugt JM; Minekawa R; Tang MH; Wang J; Oudejans CB; Lau TK; Nicolaides KH; Lo YM
    BMJ; 2011 Jan; 342():c7401. PubMed ID: 21224326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
    Cohen PA; Flowers N; Tong S; Hannan N; Pertile MD; Hui L
    BMC Med; 2016 Aug; 14(1):126. PubMed ID: 27558279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective chromosome analysis of 3429 amniocentesis samples in China using copy number variation sequencing.
    Wang J; Chen L; Zhou C; Wang L; Xie H; Xiao Y; Zhu H; Hu T; Zhang Z; Zhu Q; Liu Z; Liu S; Wang H; Xu M; Ren Z; Yu F; Cram DS; Liu H
    Am J Obstet Gynecol; 2018 Sep; 219(3):287.e1-287.e18. PubMed ID: 29852155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Open source non-invasive prenatal testing platform and its performance in a public health laboratory.
    Johansen P; Richter SR; Balslev-Harder M; Miltoft CB; Tabor A; Duno M; Kjaergaard S
    Prenat Diagn; 2016 Jun; 36(6):530-6. PubMed ID: 27027563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Not Available].
    Žilina O; Rekker K; Kaplinski L; Sauk M; Paluoja P; Teder H; Ustav EL; Tõnisson N; Reimand T; Ridnõi K; Palta P; Vermeesch JR; Krjutškov K; Kurg A; Salumets A
    Prenat Diagn; 2019 Dec; 39(13):1262-1268. PubMed ID: 31691324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell-free DNA analysis in maternal plasma in cases of fetal abnormalities detected on ultrasound examination.
    Benachi A; Letourneau A; Kleinfinger P; Senat MV; Gautier E; Favre R; Bidat L; Houfflin-Debarge V; Bouyer J; Costa JM;
    Obstet Gynecol; 2015 Jun; 125(6):1330-1337. PubMed ID: 26000504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cytogenetic constitution of human blastocysts: insights from comprehensive chromosome screening strategies.
    Fragouli E; Munne S; Wells D
    Hum Reprod Update; 2019 Jan; 25(1):15-33. PubMed ID: 30395265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood.
    Sehnert AJ; Rhees B; Comstock D; de Feo E; Heilek G; Burke J; Rava RP
    Clin Chem; 2011 Jul; 57(7):1042-9. PubMed ID: 21519036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing.
    Kinnings SL; Geis JA; Almasri E; Wang H; Guan X; McCullough RM; Bombard AT; Saldivar JS; Oeth P; Deciu C
    Prenat Diagn; 2015 Aug; 35(8):816-22. PubMed ID: 26013964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy.
    Sparks AB; Wang ET; Struble CA; Barrett W; Stokowski R; McBride C; Zahn J; Lee K; Shen N; Doshi J; Sun M; Garrison J; Sandler J; Hollemon D; Pattee P; Tomita-Mitchell A; Mitchell M; Stuelpnagel J; Song K; Oliphant A
    Prenat Diagn; 2012 Jan; 32(1):3-9. PubMed ID: 22223233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT.
    Keravnou A; Ioannides M; Loizides C; Tsangaras K; Achilleos A; Mina P; Kypri E; Hadjidaniel MD; Neofytou M; Kyriacou S; Sismani C; Koumbaris G; Patsalis PC
    PLoS One; 2018; 13(6):e0199010. PubMed ID: 29889893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing.
    Wong D; Moturi S; Angkachatchai V; Mueller R; DeSantis G; van den Boom D; Ehrich M
    Clin Biochem; 2013 Aug; 46(12):1099-1104. PubMed ID: 23643886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of determining the limit of detection of non-invasive prenatal testing methods.
    Fiorentino F; Bono S; Pizzuti F; Mariano M; Polverari A; Duca S; Sessa M; Baldi M; Diano L; Spinella F
    Prenat Diagn; 2016 Apr; 36(4):304-11. PubMed ID: 26815144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FetalQuant: deducing fractional fetal DNA concentration from massively parallel sequencing of DNA in maternal plasma.
    Jiang P; Chan KC; Liao GJ; Zheng YW; Leung TY; Chiu RW; Lo YM; Sun H
    Bioinformatics; 2012 Nov; 28(22):2883-90. PubMed ID: 22962347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles.
    Liao GJ; Lun FM; Zheng YW; Chan KC; Leung TY; Lau TK; Chiu RW; Lo YM
    Clin Chem; 2011 Jan; 57(1):92-101. PubMed ID: 21078840
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benefits and limitations of whole genome versus targeted approaches for noninvasive prenatal testing for fetal aneuploidies.
    Boon EM; Faas BH
    Prenat Diagn; 2013 Jun; 33(6):563-8. PubMed ID: 23613171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service.
    Lau TK; Jiang FM; Stevenson RJ; Lo TK; Chan LW; Chan MK; Lo PS; Wang W; Zhang HY; Chen F; Choy KW
    Prenat Diagn; 2013 Jun; 33(6):602-8. PubMed ID: 23553438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.